Limits...
Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain.

Iwatsuki K, Arai T, Ota H, Kato S, Natsume T, Kurimoto S, Yamamoto M, Hirata H - PLoS ONE (2013)

Bottom Line: Etanercept treatment improved recovery of motor nerve conduction velocity, muscle weight loss, and sciatic functional index.Etanercept reduced expression of interleukin-6 and monocyte chemotactic and activating factor-1 at the crushed sciatic nerve.Etanercept does not impede the onset or progression of Wallerian degeneration, but optimizes the involvement of macrophages and the secretion of inflammatory mediators.

View Article: PubMed Central - PubMed

Affiliation: Department of Hand Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan. kiwatsuki@med.nagoya-u.ac.jp

ABSTRACT
Tumor necrosis factor-α plays important roles in immune system development, immune response regulation, and T-cell-mediated tissue injury. The present study assessed the net value of anti-tumor necrosis factor-α treatment in terms of functional recovery and inhibition of hypersensitivity after peripheral nerve crush injury. We created a right sciatic nerve crush injury model using a Sugita aneurysm clip. Animals were separated into 3 groups: the first group received only a skin incision; the second group received nerve crush injury and intraperitoneal vehicle injection; and the third group received nerve crush injury and intraperitoneal etanercept (6 mg/kg). Etanercept treatment improved recovery of motor nerve conduction velocity, muscle weight loss, and sciatic functional index. Plantar thermal and von Frey mechanical withdrawal thresholds recovered faster in the etanercept group than in the control group. On day 7 after crush injury, the numbers of ED-1-positive cells in crushed nerves of the control and etanercept groups were increased compared to that in the sham-treated group. After 21 days, ED-1-positive cells had nearly disappeared from the etanercept group. Etanercept reduced expression of interleukin-6 and monocyte chemotactic and activating factor-1 at the crushed sciatic nerve. These findings demonstrate the utility of etanercept, in terms of both enhancing functional recovery and suppressing hypersensitivity after nerve crush. Etanercept does not impede the onset or progression of Wallerian degeneration, but optimizes the involvement of macrophages and the secretion of inflammatory mediators.

Show MeSH

Related in: MedlinePlus

Immunohistochemical staining for macrophage marker ED-1 in crushed sciatic nerve sections.A) Sham-treated 7 days after surgery; B) control 7 days after surgery; C) etanercept-treated 7 days after surgery; D) sham-treated 21 days after surgery; E) control 21 days after surgery; and F) etanercept-treated 21 days after surgery. By 21 days, ED-1-positive cells had nearly disappeared from the etanercept group.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585184&req=5

pone-0057721-g007: Immunohistochemical staining for macrophage marker ED-1 in crushed sciatic nerve sections.A) Sham-treated 7 days after surgery; B) control 7 days after surgery; C) etanercept-treated 7 days after surgery; D) sham-treated 21 days after surgery; E) control 21 days after surgery; and F) etanercept-treated 21 days after surgery. By 21 days, ED-1-positive cells had nearly disappeared from the etanercept group.

Mentions: On day 7 after crush injury, ED-1-positive cells were observed in both control and etanercept groups. This means that macrophages were recruited from the periphery and induced WD by carrying out the removal of myelin debris while Schwann cell proliferation was concomitantly enhanced. After 21 days, ED-1-positive cells had almost disappeared in the etanercept group, whereas the control group still showed abundant ED-1-positive cells within nerve fascicles (Fig. 7).


Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain.

Iwatsuki K, Arai T, Ota H, Kato S, Natsume T, Kurimoto S, Yamamoto M, Hirata H - PLoS ONE (2013)

Immunohistochemical staining for macrophage marker ED-1 in crushed sciatic nerve sections.A) Sham-treated 7 days after surgery; B) control 7 days after surgery; C) etanercept-treated 7 days after surgery; D) sham-treated 21 days after surgery; E) control 21 days after surgery; and F) etanercept-treated 21 days after surgery. By 21 days, ED-1-positive cells had nearly disappeared from the etanercept group.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585184&req=5

pone-0057721-g007: Immunohistochemical staining for macrophage marker ED-1 in crushed sciatic nerve sections.A) Sham-treated 7 days after surgery; B) control 7 days after surgery; C) etanercept-treated 7 days after surgery; D) sham-treated 21 days after surgery; E) control 21 days after surgery; and F) etanercept-treated 21 days after surgery. By 21 days, ED-1-positive cells had nearly disappeared from the etanercept group.
Mentions: On day 7 after crush injury, ED-1-positive cells were observed in both control and etanercept groups. This means that macrophages were recruited from the periphery and induced WD by carrying out the removal of myelin debris while Schwann cell proliferation was concomitantly enhanced. After 21 days, ED-1-positive cells had almost disappeared in the etanercept group, whereas the control group still showed abundant ED-1-positive cells within nerve fascicles (Fig. 7).

Bottom Line: Etanercept treatment improved recovery of motor nerve conduction velocity, muscle weight loss, and sciatic functional index.Etanercept reduced expression of interleukin-6 and monocyte chemotactic and activating factor-1 at the crushed sciatic nerve.Etanercept does not impede the onset or progression of Wallerian degeneration, but optimizes the involvement of macrophages and the secretion of inflammatory mediators.

View Article: PubMed Central - PubMed

Affiliation: Department of Hand Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan. kiwatsuki@med.nagoya-u.ac.jp

ABSTRACT
Tumor necrosis factor-α plays important roles in immune system development, immune response regulation, and T-cell-mediated tissue injury. The present study assessed the net value of anti-tumor necrosis factor-α treatment in terms of functional recovery and inhibition of hypersensitivity after peripheral nerve crush injury. We created a right sciatic nerve crush injury model using a Sugita aneurysm clip. Animals were separated into 3 groups: the first group received only a skin incision; the second group received nerve crush injury and intraperitoneal vehicle injection; and the third group received nerve crush injury and intraperitoneal etanercept (6 mg/kg). Etanercept treatment improved recovery of motor nerve conduction velocity, muscle weight loss, and sciatic functional index. Plantar thermal and von Frey mechanical withdrawal thresholds recovered faster in the etanercept group than in the control group. On day 7 after crush injury, the numbers of ED-1-positive cells in crushed nerves of the control and etanercept groups were increased compared to that in the sham-treated group. After 21 days, ED-1-positive cells had nearly disappeared from the etanercept group. Etanercept reduced expression of interleukin-6 and monocyte chemotactic and activating factor-1 at the crushed sciatic nerve. These findings demonstrate the utility of etanercept, in terms of both enhancing functional recovery and suppressing hypersensitivity after nerve crush. Etanercept does not impede the onset or progression of Wallerian degeneration, but optimizes the involvement of macrophages and the secretion of inflammatory mediators.

Show MeSH
Related in: MedlinePlus